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Effective correction of hyperhomocysteinemia in hemodialysis teinemia, attempts have been made to lower plasma tHcy
patients by intravenous folinic acid and pyridoxine therapy. concentrations in HD patients. Several studies in HD
Background. Folic acid supplementation is only partially ef- patients have shown that supplementation with pharma-ficacious in correcting moderate elevation of plasma total
cological doses of folic acid (2.5 to 15 mg/day), eitherhomocysteine (tHcy) concentrations observed in hemodialysis
alone or combined with other B vitamins, reduced plasma(HD) patients. Experimental and clinical data have suggested
that this partial efficacy may be due to impairment of folic tHcy levels by approximately 30 to 40% [4–6]. However,
acid metabolism to 5-methyltetrahydrofolate (MTHF) and of it became clear that folic acid supplementation was only
MTHF transmembrane transport as well. To bypass these dif-
partially effective in reducing tHcy levels, and only aficulties, we assessed the efficacy of intravenous (i.v.) folinic
few HD patients entirely normalized their levels [4–6].acid, a ready precursor of MTHF, on reducing plasma tHcy
concentrations in HD patients. Recently, the use of 5-methyltetrahydrofolate (MTHF),
Methods. In a cohort of 37 patients on intermittent HD the circulating reduced form of folate at an oral dose of
treatment, plasma tHcy concentrations were determined be- 15 mg/day (105 mg/week) for two months has beenfore and during i.v. supplementation of folinic acid (50 mg
shown to lead to a significant decrease (70%) in plasmaonce per week), together with i.v. pyridoxine (250 mg 3 times
per week), to prevent vitamin deficiency, particularly in those tHcy levels in 14 HD patients, with 5 patients achieving
treated by recombinant erythropoietin. tHcy levels below 15 mm, which is the upper limit of
Results. Folinic acid and pyridoxine i.v. supplementation was normal in this study [7]. The difference in efficacy ob-
given for 11.2 6 2.45 months (range 7.5 to 17 months). The
served between folic acid and MTHF supplementationmean plasma tHcy levels decreased significantly from 37.3 6
may be due to better absorption of the latter. Folic acid5.8 mm at baseline to 12.3 6 5.4 mm on folinic acid treatment
(P , 0.001). Moreover, 29 of the 37 patients (78%) had normal (pteroylglutamic acid) usually needs to undergo reduction
plasma tHcy levels at the end of follow-up (that is, ,14.1 mm, and methylation to MTHF in the small gut during intesti-
mean 9.8 mm, range 6.2 to 13 mm). No adverse effects attribut-
nal absorption before reaching the portal blood system,able to folinic acid treatment were observed during this time.
whereas MTHF bypasses these latter steps [8, 9]. HigherConclusions. Intravenous folinic acid therapy (50 mg) once
per week associated with pyridoxine supplementation appears circulating MTHF levels with MTHF than with folic acid
to be an effective and safe strategy to normalize plasma tHcy supplementation may lead to the overcoming of the im-
levels in the majority of chronic HD patients. pairment of MTHF transmembrane transport observed
in HD patients [10] and to the deliverance of a sufficient
amount of readily available substrate for methionine syn-
Moderate elevation of plasma total homocysteine thase for the re-methylation of Hcy to methionine [11].
(tHcy) concentrations is present in the majority of hemo- However, limited data in uremic rats [12] and uremic
dialysis (HD) patients [1], and it is associated with an patients [13] have suggested that the intestinal absorp-
increased risk of cardiovascular disease in such patients tion of MTHF is impaired in chronic renal failure. In light
[2, 3]. In view of the atherogenic role of hyperhomocys-
of this information, it is conceivable that the intravenous
(i.v.) administration of MTHF could be preferable to
oral administration to reach higher plasma MTHF levelsKey words: dialysis, folic acid, methyltetrahydrofolate, total homocys-
teine. in such patients.
In our center, because we have observed that a high
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Table 1. Characteristics of 37 hemodialysis patients before (Ti) andin HD patients to prevent folate deficiency, particularly
during (Tf) intravenous folinic acid treatment
in those treated by recombinant erythropoietin. Folinic
Ti Tfacid, which is the formyl form of tetrahydrofolate, is the
(N 5 37) (N 5 37) Ponly form available for i.v. administration in France.
Plasma tHcy lm 37.365.8 12.3 65.4 ,0.001Folinic acid is rapidly converted to MTHF in plasma [14,
Plasma tHcy , 14.1 mm
15]. Because we routinely measured the plasma tHcy % of patients 0 78 ,0.001
Plasma folate nm 24.363.7 40.6 66.8 ,0.001concentration once a year in HD patients, we took the
Erythrocyte folate nm 321636 18256356 ,0.001opportunity to assess the efficacy of i.v. folinic acid on
Plasma vitamin B12 pm 192630 358 661 ,0.001reducing plasma tHcy concentrations in such patients. Plasma albumin g/liter 35.163.4 36.2 63.1 NS
Abbreviation is: tHcy, total homocysteine.
METHODS
Thirty-seven HD patients were selected, provided they
were being treated by regular bicarbonate HD treatment state before and during folinic acid therapy, immediately
(the mean time of follow-up since the first HD session before the a HD session. Plasma tHcy concentrations
was 32.4 months, range 9 to 204 months), were treated were measured using the radioenzymatic method [16].
by i.v. supplementation of folinic acid, and had plasma Normal tHcy concentrations were 8.2 6 2.2 mm (upper
tHcy concentration assessment before and during folinic limit of normal range, 14.1 mm). Plasma and erythrocyte
acid treatment. Five of the 37 patients had an oral supple- folate concentrations, as well as plasma vitamin B12 con-
mentation of folic acid (5 mg/day for 7 6 2.3 months) centrations, were determined using a commercial radio-
prior to i.v. folinic acid administration, with only minor isotope assay (Chiron Diagnostic, St Ouen-l’Aumoˆne,
effects on the plasma tHcy concentration [from 27 6 France; normal range, 7 to 34 nm for plasma folate, 300
11.4 to 22.5 6 7.2 mm (P 5 NS) before and during folic to 1400 nm for erythrocyte folate, and 150 to 750 pm for
acid oral supplementation, respectively]. This inefficacy plasma vitamin B12).
was due to either poor compliance or reduced intestinal Results are expressed as mean 6 sd. Student’s paired
absorption, as attested by a negligible increase of plasma and unpaired t-test and chi-square test were used to
folate (26 6 15 vs. 31 6 10 nm, P 5 NS) and erythrocyte evaluate differences between groups. The Spearman–
folate (310 6 56 vs. 450 6 26 nm, P 5 NS) levels observed Pearson test was used to evaluate the relationship be-
after oral folic acid supplementation. The remaining 32 tween numeric variables. P values , 0.05 were consid-
patients either were not taking oral folic acid supplemen- ered to be significant.
tation for socioeconomic reasons or were referred to
our nephrology division to dialysis after we started to
RESULTSprescribe i.v. folinic acid supplementation routinely with-
out previous oral folic acid supplementation. The effects of folinic acid and pyridoxine are shown
in Table 1. Data from individual patients are shown inThe patients were 21 men and 16 women with a mean
age of 56.7 6 18.1 years (mean 6 sd). Primary renal Figure 1. The mean plasma tHcy levels were significantly
lower (by 67%) during than at start of folinic acid treat-disease was chronic glomerulonephristis (5 HD patients),
chronic interstitial nephritis (7), hypertensive nephro- ment. Moreover, 29 of 37 HD patients (78%) had achieved
normal plasma tHcy levels (that is, ,14.1 mm, mean 9.8 mm,sclerosis (4), polycystic kidney disease (3), diabetic ne-
phropathy (4), systemic diseases (6), other and undeter- range 6.2 to 13.0 mm). It is noteworthy that both patients
with systemic disease (N 5 6) and patients who were undermined (8). They were hemodialyzed using high-flux
synthetic membrane (10 HD patients) or a low-flux syn- oral folic acid supplementation with only minor effects
on plasma tHcy concentration (N 5 5) normalized theirthetic or cellulosic membrane (27). Thirty-three of them
were receiving recombinant erythropoietin therapy. The plasma tHcy levels. Eight patients, in whom plasma tHcy
concentrations were not normalized, experienced a sub-percentage of urea reduction was routinely checked at
monthly intervals and was always above 70%. stantial decrease in tHcy levels (47%; Table 2). Except
for a longer period of folinic acid treatment in patientsAll patients received an i.v. supplementation of 50 mg
folinic acid [Calcium folinatet (racemic mixture of l- and who did normalize plasma tHcy than in patients who did
not and a tendency in males (18 out of 21 patients) tod-isomers); Dakota Pharm, Creteil, France] at the end
of the first HD session of each week. They also routinely normalize tHcy levels more frequently than females (11
out of 16), other characteristics of two groups were simi-received i.v. pyrodixine (250 mg 3 times per week). Two
of them also received oral vitamin B12 (1 mg/day). Folinic lar (Table 2). tHcy levels during folinic acid treatment
were negatively correlated with the duration of folinicacid i.v. supplementation was given for 11.2 6 2.5 months
(range 7.5 to 17 months). acid treatment (r 5 20.46, P , 0.004) and positively
with tHcy levels before folinic acid treatment (r 5 0.42,Blood was drawn while the patient was in the fasting
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P , 0.001). No adverse effects could be attributed to
folinic acid treatment during the period of follow-up.
DISCUSSION
Our data show that a once weekly i.v. administration
of 50 mg folinic acid together with pyridoxine is highly
effective in correcting the hyperhomocysteinemia of HD
patients, as attested by normalization of plasma tHcy
levels in 29 (78%) and the substantial decrease (47%)
in 9 patients. We found no evidence of toxicity associated
with this treatment regimen.
Our results emphasize the importance of folate metab-
olism in the regulation of plasma tHcy levels in HD
patients. The difficulty of reaching acceptable circulating
MTHF levels in HD patients, which in turn are capable
of decreasing plasma tHcy levels in HD patients, appears
to play a central role. The reduction of MTHF intestinal
absorption and/or production could be one of the factors
explaining this latter difficulty [8, 9, 12, 13]. An alterna-
tive mechanism could be that HD patients require phar-
macological MTHF concentrations to overcome the im-
pairment of MTHF transmembrane transport [10]. It
is possible that only oral, or even better i.v., MTHF
supplementation could deliver such quantity. The fact
that a once weekly i.v. MTHF supplementation (50 mg)
leads to normalization of plasma tHcy levels in a much
higher percentage of HD patients than the daily oral
administration of folic acid (17.5 to 105 mg/week) [4–6]
or MTHF (105 mg/week) [7] is in line with this explana-
tion. In vitro, the accumulation of factors related to the
uremic state has been shown to be associated with the
inhibition of MTHF absorption and transmembrane
transport, which can be improved by dialysis treatment,
suggesting that these defects are due to the uremic envi-
ronment rather than an acquired intrinsic defect of cells
in uremia [10, 12]. However, the fact that 22% of HD
patients did not entirely normalize plasma tHcy levels
suggests that factors other than uremia are implicated
in MTHF metabolism abnormalities, although we cannot
exclude the possibility that some HD patients (for ge-
netic or environmental reasons) require higher circulat-
ing MTHF levels or longer periods of folinic acid treat-
ment than those achieved in this study to normalize
plasma tHcy. The close relationship between tHcy con-
centrations and the duration of folinic acid treatment is
an argument in favor of this explanation.
A comparison between plasma and/or erythrocyte fo-Fig. 1. Plasma total homocysteine, plasma folate, and erythrocyte fo-
late concentrations of individual patients before (Ti) and during (Tf) late levels in patients treated by i.v. folinic acid and in
intravenous folinic acid treatment. patients treated with oral folic acid could not be done in
this study, as measurement of plasma and/or erythrocyte
folate was performed only in patients on i.v. folinic acid
therapy and in noncompliant patients. However, by using
i.v. folinic acid, we could show that a twofold increase
of plasma folate levels was sufficient to normalize plasma
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Table 2. Characteristics of hemodialysis (HD) patients who did (responders) or did not (partial responders) normalize plasma total
homocysteine (tHcy) concentrations under intravenous folinic acid treatment
Responders (N 5 29) Partial responders (N 5 8)
Ti Tf Ti Tf
Age years 57618 — 54619 —
Males/females 18/11 — 3/5 —
Time since first HD months 33635 — 29611 —
High flux membrane % 27 — 25 —
Treatment duration months — 11.7 62.4 — 9.461.6d
Plasma tHcy lm 36.665.1 9.861.8a 40.167.6 21.463.9b,c
Plasma folate nm 26.766.2 4263.1a 23.468.1 4166b
Erythrocyte folate nm 328633 17006408a 330646 15706520b
Plasma vitamin B12 pm 196627 361646a 180632 350675b
Plasma albumin g/liter 34.564.2 36 63.7 35.762.5 36.563.4
Abbreviations are: Ti, before folinic acid treatment; Tf, under folinic acid treatment; tHcy, total homocysteine.
a P , 0.001 vs. Ti of responders
b P , 0.001 vs. Ti of partial responders
c P , 0.05 vs. Tf of responders
d P , 0.02 vs. Tf of responders
tHcy levels in 78% of HD patients. Our data are in although we do not see any obvious rationale for such
an explanation.contrast with previous reports, which demonstrated that
oral folic acid supplementation (up to 15 mg/day) led to A spontaneous increase of plasma vitamin B12 levels
was observed in all but two of our patients. The lattera 20- to 50-fold increase of plasma folate levels, but could
not normalize plasma tHcy levels in more than 10 to were on oral vitamin B12 (1 mg/day) supplements for low
plasma vitamin B12 levels (,150 pm). This spontaneous30% of thus treated dialysis patients [4, 6]. Because high
oral doses of folic acid (.2 to 3 mg) increase both folic increase was almost certainly due to a better nutritional
status under erythropoietin therapy and due to the startacid and MTHF in the serum [17, 18], it is possible that
this discrepancy is due to an alteration of the reduction of dialysis therapy in some of them. Whereas vitamin
B12 deficiency could increase plasma tHcy levels, vitaminof folic acid to MTHF in the plasma of HD patients.
Recently, Livant et al reported the presence of an un- B12 supplementation could do the opposite in HD pa-
tients with a vitamin B12 deficiency [24]. However, itidentified inhibitor(s) of plasma folate conjugase (the
enzyme responsible for reducing polyglutamate folate to remains unclear whether an administration of vitamin
B12 in addition to folate therapy might further improvemonoglutamate folate) in HD patients [19]. However,
we could not use the determination of plasma and/or the reduction of plasma tHcy observed in HD patients
without a vitamin B12 deficiency, as was the case in theerythrocyte folate levels to verify our hypothesis that it
is important to reach an acceptable circulating MTHF majority of our patients. Moreover, it has been shown
in a recent study that the addition of 1 mg/day vitaminlevel, as the folate assays currently available for clinical
practice measure all folate derivatives, including MTHF B12 to an oral dose of 15 mg/day folic acid led to an
increase of plasma vitamin B12 levels, which was of the[20]. Thus, it may be difficult to evaluate the efficacy
of various folate treatment strategies, based solely on same order of magnitude as the elevation of plasma
vitamin B12 levels in this work. However, this combina-currently available commercial assays, and a direct deter-
mination of circulating MTHF is warranted to assess tion therapy was only partially effective in reducing tHcy
levels in that study, as only a few HD patients entirelysuch efficacy [14, 15, 17, 18, 21].
The addition of i.v. pyridoxine therapy to i.v. folinic normalized their levels [4].
Besides the absence of plasma MTHF measurementsacid supplementation could have contributed to the ef-
fectiveness of our strategy to normalize plasma tHcy in all of our patients, this work has another important
limitation, namely the lack of a controlled and prospec-levels in HD patients. However, we previously observed
that oral pyridoxine supplementation (70 mg/day) has tive study design. Nevertheless, it reports for the first
time an effective and probably safe strategy that leadsno significant effect on fasting total Hcy levels in nondia-
lyzed chronic renal failure patients [22]. Moreover, it to normalization of plasma tHcy levels in the majority
of HD patients and offers new insights into the potentialwas demonstrated that an oral pyridoxine supplementa-
tion of 300 mg/day had no effect on fasting total Hcy role of MTHF as a determinant of plasma tHcy levels
in such patients. Whether a higher dose and/or a longerlevels in a mixed group of HD and PD patients [23]. It
remains possible, however, that i.v. pyridoxine supple- time period of i.v. MTHF administration once weekly
may lead to the normalization of plasma tHcy levels inmentation has a greater efficacy than oral pyridoxine,
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